05 March 2019 | News
Halodoc will use the new funds to perfect the online to offline healthcare experience with hospitals and insurance partners as its roll-out continues in 2019
Halodoc, Indonesia's leading healthcare platform, has raised US$65 million in Series B funding, led by new investor UOB Venture Management. Other new investors in the financing round include Singtel Innov8, Korea Investment Partners and WuXi AppTec. Existing investors also participated.
Halodoc is a digital healthcare platform that includes a mobile app and website allowing customers across Indonesia to have live consultations with more than 20,000 licensed doctors in the country, anytime, anywhere. Its platform usage grew by 2500% in 2018, demonstrating robust demand for healthcare convenience. Customers can order lab tests to be carried out in their home and use the app to order medication from 1,300 participating pharmacies, which can be delivered within an hour.
Halodoc has teamed with more than 1,400 hospitals and healthcare providers in a nationwide partnership to improve the hospital visit experience. The partnership provides customers with shortened wait times at the pharmacy post appointment and a cashless hospital visit through linking of insurance benefits. Halodoc will use the new funds to perfect the online to offline healthcare experience with hospitals and insurance partners as its roll-out continues in 2019.
Halodoc was named "Most Innovative Start-up in Asia in November 2018" by Galen Growth Asia, an organisation that monitors the healthcare start-up ecosystem in Asia Pacific.
Halodoc has worked closely with its existing investors, Openspace Ventures, Clermont Group, Blibli.com and InvestIdea who share a similar vision for the future of healthcare. Whilst Halodoc's strategic partner GOJEK Group, continues its commitment to Halodoc's success.